More about Acyclovir Neurotoxicity in Patients on Haemodialysis

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Acyclovir is an efficient treatment in virus infections of the herpes family. Now that it has been in use for more than 10 years, neurotoxicity is a well-known complication, especially after the intravenous use [1]. However, recently cases of neurotoxicity after the oral use in patients with terminal renal failure (TRF) on haemodialysis (HD) have been described [2–5]. This has been associated with high serum levels of the drug, representing an overdose and a significant modification of the dosage has been recommended in these patients [2, 4, 5]. HD has been shown to be an efficient method of elimination as well as a diagnostic method to differentiate between acyclovir neurotoxicity and encephalitic herpes [6].

Related collections

Author and article information

Journal

Journal ID (publisher-id): NEF

Journal ID (nlm-ta): Nephron

Journal ID (doi): 10.1159/issn.1660-8151

Title: Nephron

Publisher: S. Karger AG

ISSN (Print): 1660-8151

ISSN (Electronic): 2235-3186

Publication date Subscription-year: 1998

Publication date (Print): February 1998

Publication date (Electronic): 26 January 1998

Volume: 78

Issue: 2

Pages: 228-229

Affiliations

Servicio de Nefrología, Hospital General Universitario ‘Gregorio Marañón’, Madrid, Spain

Article

Publisher ID: 44919 Other ID: Nephron 1998;78:228–229

DOI: 10.1159/000044919

PubMed ID: 9496746

SO-VID: f29a21a1-d559-41bd-ae92-eec48ef5694a

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

Submit here before July 31, 2024

More about Acyclovir Neurotoxicity in Patients on Haemodialysis

Read this article at

Abstract

Related collections

Karger: Nephrology

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 534

Cited by 1